



24 May 2012

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Results of Annual General Meeting on 24 May 2012

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out below.

Item 1 – Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
148,345,840	118,633	-	25,000

This resolution was passed on a show of hands.

Item 2 – Re-Election of Mr Vanda Gould

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
148,459,302	-	5,171	25,000

This resolution was passed on a show of hands.

Item 3 – Share Buy-back

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
148,450,589	13,884	-	25,000

This resolution was passed on a show of hands.

Item 4 – Issue of shares to the Managing Director

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
148,321,243	143,230	-	25,000

This resolution was passed on a show of hands.

Item 5 – Consolidation of Share Capital

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
148,389,814	74,659	-	25,000

This resolution was passed on a show of hands.



James McBrayer
Managing Director and Company Secretary

Contact details:

Mr James McBrayer
Managing Director
Cyclopharm Limited
T: +61 2 9541 0411

Background

Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the medical global medical community. The Company's mission is to enable nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Positron Emission Tomography (PET)

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed.

Macquarie University Hospital and the Macquarie University School of Advanced Medicine

Macquarie University Hospital is a major medical precinct within the Macquarie University Research Park to complement the Allied Health teaching services offered by Macquarie University.

The Macquarie University Hospital is a state of the art facility that delivers health education and research on site.

Macquarie Medical Imaging

Cyclopharm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide all imaging services on-site at the hospital. The new venture named Macquarie Medical Imaging ("MMI") represents a rare strategic opportunity to provide a fully aligned and integrated diagnostic, therapeutic and research platform. MMI offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients.

The combination of state of the art imaging equipment, a GE cyclotron located on the grounds of MUH, leading surgeons, clinicians and academics will ensure that MMI will become the leading centre of imaging excellence.